Summary
This study is to evaluate the potential of a lab test using patient tumour samples (called tumour organoid response) to predict the clinical benefit that individual patients may get from available anti-cancer treatments for advanced bowel cancer, in both the first- and later-line therapy settings.
Who is it for?
You may be eligible for this study if you are an adult with a diagnosis of colorectal cancer that is either locally advanced and unable to be removed with surgery (unresectable), or metastatic. You should not have received treatment (e.g. chemotherapy) for this stage of disease and be otherwise fit enough to undertake treatment.
Study details
The study will involve obtaining biopsies, initially and at the time of cancer progression, and using standard and new blood tests.
Patients will receive standard of care treatment at the discretion of their Oncologist (this is standard practise, done for those not participating in clinical trials also).
The consistency of results between expanded panel (TSO500) based testing of tumour tissue and laboratory-based profiling of the matrched PDTO will be examined.
It is hoped that these results will help improve decision making by clinicians and ultimately individualise patients' treatment to improve outcomes. It is hoped the findings from this study will establish reliable preclinical models that will enable high throughout drug testing to guide optimal treatment selection in daily clinical practice in the future, and potentially inform treatment selection of standard of care agents in first and later line treatment.